Evidence map›Paper›PMID 36096751›Full record

SynthesisBMC neurology2022

Optimal therapeutic conditions for the neural stem cell-based management of ischemic stroke: a systematic review and network meta-analysis based on animal studies.

Yongna Yang, Xurui Hu, Qijie Qin, Fanling Kong, Xiaolan Peng, Jing Zhao, Jianghua Si, Zhilong Yang, Shoupin Xie

Open access · goldAbstract readSystematic ReviewNetwork Meta-Analysis
In one paragraph

Synthesis in BMC neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Research progress and challenges of stem cell therapy for ischemic stroke.Frontiers in cell and developmental biology · 2024
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yongna YangThe first people' s hospital of lanzhou city, Lanzhou, 730000, China.
Xurui HuThe first people' s hospital of lanzhou city, Lanzhou, 730000, China.
Qijie QinThe first people' s hospital of lanzhou city, Lanzhou, 730000, China. qijieqin@126.com.
Fanling KongThe first people' s hospital of lanzhou city, Lanzhou, 730000, China.
Xiaolan PengThe first people' s hospital of lanzhou city, Lanzhou, 730000, China.
Jing ZhaoThe first people' s hospital of lanzhou city, Lanzhou, 730000, China.
Jianghua SiThe first people' s hospital of lanzhou city, Lanzhou, 730000, China.
Zhilong YangThe first people' s hospital of lanzhou city, Lanzhou, 730000, China.
Shoupin XieThe first people' s hospital of lanzhou city, Lanzhou, 730000, China.
Lanzhou University · CNFirst Hospital of Lanzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn order to promote the clinical translation of preclinical findings, it is imperative to identify the most optimal therapeutic conditions and adopt them for further animal and human studies. This study aimed to fully explore the optimal conditions for neural stem cell (NSC)-based ischemic stroke treatment based on animal studies.

methodsThe PubMed, Ovid-Embase, and Web of Science databases were searched in December 2021. The screening of search results, extraction of relevant data, and evaluation of study quality were performed independently by two reviewers.

resultsIn total, 52 studies were included for data analysis. Traditional meta-analysis showed that NSCs significantly reduced the modified neurological severity score (mNSS) and volume of cerebral infarct in animal models of ischemic stroke. Network meta-analysis showed that allogeneic embryonic tissue was the best source of NSCs. Further, intracerebral transplantation was the most optimal route of NSC transplantation, and the acute phase was the most suitable stage for intervention. The optimal number of NSCs for transplantation was 1-5×10

conclusionsWe systematically explored the therapeutic strategy of NSCs in ischemic stroke, but additional research is required to develop optimal therapeutic strategies based on NSCs. Moreover, it is necessary to further improve and standardize the design, implementation, measuring standards, and reporting of animal-based studies to promote the development of better animal experiments and clinical research.

Indexed as

Ischemic StrokeNeural Stem CellsStrokeAnimalsHumansMiceRatsStem Cell TransplantationAnimal studiesIschemic strokeNetwork meta-analysisNeural stem cellsSystematic reviewTherapeutic strategies

Identifiers

PMID36096751
PMCPMC9469626
OpenAlexW4295420346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.